Today, the World Health Organization (WHO) launched an enhanced version of its Global Antimicrobial Resistance and Use Surveillance System (GLASS) dashboard , advancing global efforts to improve worldwide monitoring of antimicrobial resistance (AMR) and use (AMU).
The dashboard includes AMR and AMU data for the period 2016–2023, as reported by 141 countries, territories, and areas (CTAs) participating in the WHO global surveillance initiative.
It presents data at global, regional, and national levels, including individual CTA profiles, and expands and complements the insights provided in GLASS reports . While the reports highlight key findings and offer actionable recommendations, the dashboard provides direct access to the underlying data, supporting transparent dissemination.
GLASS data visualization dashboard for AMR
The GLASS-AMR dashboard provides a comprehensive view of crude AMR data used to generate national, regional or global modelled estimates of surveillance coverage, antibiotic resistance and trends featured in the forthcoming Global Antibiotic Resistance Surveillance Report, 2025.
Key features of the GLASS-AMR dashboard
- Includes over 23 million bacteriologically confirmed infection episodes reported by 110 CTAs contributing to GLASS between 2016 and 2023.
- Presents AMR data for eight bacterial pathogens frequently isolated from patients with bloodstream, gastrointestinal, urinary, or urogenital gonorrhoea infections.
- Displays resistance to 23 antibiotics across 11 antibiotic classes.
- Enables filtering by CTA, region, pathogen, and antibiotic to support targeted data exploration.
Surveillance system insights
The dashboard also monitors progress in national AMR system implementation and surveillance coverage between 2016 and 2023, including:
- Number of CTAs reporting antibiotic susceptibility test (AST) results.
- Number of bacteriologically confirmed infection episodes reported with AST.
- Number of infection episodes with AST reported per million population, shown as the median across CTAs.
Visual presentation of AMR data
- Crude median proportions of AMR for 2023 are presented at global and regional levels, with consideration given to differences in AMR surveillance coverage across CTAs.
- Time series of crude resistance proportions are available for CTAs that submitted susceptibility data for at least 70% of the years between 2018 to 2023. For WHO regions with data from five or more CTAs, time series are summarized using medians and interquartile ranges of national observations.
GLASS data visualization dashboard for antimicrobial use
The GLASS-AMU dashboard presents national data on the use of systemic antimicrobials – including antibiotics, antifungals, antivirals, anti-tuberculosis medicines, and antimalarials – covering the period from 2016 to 2023.
For each year, the dashboard highlights key data characteristics to support interpretation. As detailed in the latest GLASS-AMU report , AMU is measured in Defined Daily Doses (DDDs) and presented both as density of use (DDD per 1000 inhabitants per day) and as usage patterns. The main focus remains on antibiotic use, which is described in terms of overall use, by WHO AWaRe classification , antibiotic subgroups, route of administration, and the most commonly used antibiotics. For the first time, users can also explore subgroup-level data for other antimicrobial classes.
The dashboard is organized into two main sections:
The Global AMU section presents annual data at the global level, with breakdowns by WHO region and income level. Indicators are shown as distributions across countries (with medians and interquartile ranges) and by individual countries. Users can also view time trends for selected countries and download datasets.
The country, territory or area profiles section allows users to view a CTA profile, including tables and time series from 2016 to 2023. A downloadable PDF version of each profile is available, summarizing key indicators.
Highlights
As of December 2023, 98 CTAs had enrolled in GLASS-AMU. Of these, 68 reported data for 2023 and an additional 10 had reported at least once for the years 2016–2022. The current dashboard displays validated data from 73 CTAs. In 2023, 57% of total antibiotic use globally came from 'Access' antibiotics, and only one in three CTAs (22 of 65; 34%) met the WHO target of at least 70% of national antibiotic use being from 'Access' antibiotics.
